Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
European Journal of Cancer2019Vol. 121, pp. 177–183
Citations Over TimeTop 10% of 2019 papers
Lisa M. Kopp, Suman Malempati, Mark Krailo, Yun Gao, Allen Buxton, Brenda J. Weigel, Thomas Hawthorne, Elizabeth Crowley, Jeffrey A. Moscow, Joel M. Reid, Víctor M. Villalobos, R. Lor Randall, Richard Görlick, Katherine A. Janeway
Related Papers
- → Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer(2007)26 cited
- → Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated MGMT gene promoter: RACTAC, a phase II multicenter trial(2023)14 cited
- → Rechallenge with lamotrigine after initial rash(1995)64 cited
- → 265O Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial(2020)10 cited
- → Investigation on accuracy of triage of the pediatric patients with rash(2010)